⁃ Patients with AML who are not suitable for intensive chemotherapy according to the WHO diagnosis: age ≥60 years or age \<60 years but fulfil the following criteria;

• Age 18 to 59 years;

• Eastern Cooperative Oncology Group (ECOG) physical status score of 2 or 3;

• Expected survival time ≥3 months;

• Or fulfilment of severe cardiac, pulmonary, hepatic, or renal disease; (A) Presence of a cardiac history of congestive heart failure, or ejection fraction ≤ 50%, or presence of chronic stable angina; (B) Lung carbon monoxide diffusing capacity (DLCO) ≤ 65%, or first forced expiratory volume (FEV1) ≤ 65%; (C) Moderate hepatic impairment with total bilirubin \> 1.5 to ≤ 3.0 x upper limit of normal (ULN); (D) Creatinine clearance ≥ 30 mL/min to \< 45 mL/min;

• Not received radiotherapy, treatment regimens other than the VA regimen, or haematopoietic stem cell transplantation within 4 weeks prior to enrolment;

• Other comorbidities that, in the judgement of the physician, make the administration of intensive chemotherapy unsuitable;

• Ability to understand and willingness to sign the informed consent for this trial;

• The patient refuses intensive chemotherapy and has the willingness to accept non-intensive chemotherapy.